You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱景生物(688068.SH):糖譜科技擬增資擴股並受讓公司抗體研發項目及部分儀器設備
格隆匯 12-10 18:54

格隆匯12月10日丨熱景生物(688068.SH)公佈,經公司董事會審議一致通過全資子公司糖譜(北京)科技有限公司(“糖譜科技”)增資擴股的議案,糖譜科技擬增加註冊資本900萬元,分別由公司、林長青、孫志偉增資450萬元、350萬元和100萬元。增資完成後,糖譜科技以資產評估價格224.996萬元,受讓熱景生物的“H2007治療性單克隆抗體研發項目”,同時以淨值45.91萬元購買該項目相關的研發用儀器設備,以43.8萬元/年的價格租賃公司的研發場地;交易金額合計314.70萬元。

公司持續聚焦體外診斷主業的同繼續公司在前沿探索性H2007治療性單克隆抗體研發項目”的研發,並最大程度減少研發失敗風險對公司主營業務影響;公司擬通過糖譜科技增資擴股並受讓H2007治療性單克隆抗體研發項目”的方式,由該控股子公司承接研發。

糖譜科技擬按照註冊資本原值增資900萬元,分別由公司林長青、孫志偉,增加出資450萬元350100萬元以上出資,全部計入糖譜科技註冊資本。此次增資完成後,糖譜科技註冊資本由100萬元增至1000萬元,公司所持糖譜科技股權比例自100%降至55%。同時,糖譜科技擬更名為“北京遠景抗體藥物有限公司”(暫定名,最終名稱以工商變更登記為準)。增資完成後,糖譜科技受讓公司的H2007治療性單克隆抗體研發項目”以及部分儀器設備,同時租賃公司的研發場地。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account